• Conexeu disclosed completion of the 12-month P.R.O.O.F. phase in its CXU preclinical program for an ECM-based biomaterial scaffold.
• Study met predefined objectives in a small-volume facial tissue model, also in a large-volume subcutaneous model at about 200cc-equivalent volume.
• Company flagged the program as investigational, preclinical-stage, positioning CXU as a multi-component collagen-ECM scaffold for soft-tissue restoration.
• Detailed 12-month findings, quantitative analyses, and histology endpoints were held for scientific presentation, also peer-reviewed publication.
• Conexeu noted those preclinical volumes do not establish appropriate or safe dosing levels in humans.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Conexeu Sciences Inc. published the original content used to generate this news brief on August 18, 2026, and is solely responsible for the information contained therein.